ICLR logo

ICON PLC

ICLRNASDAQ
πŸ† #634 by market capEarnings Oct 28US Equity
$823.71β–Ό $29.90 (βˆ’3.63%)
Simulated price
1hβ€”
24hβ–Ό 3.6%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$12.81B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+3.0%
Slowing
πŸ“ŠGross Margin
24.2%
Moderate
πŸ’΅FCF Margin
10.6%
Healthy
βš–οΈP/S Ratio
1.5x
Cheap
Otter Score
51
Weak
No chart data available for ICLR.

Trading Snapshot

Day Range
$814.26 – $827.20
52-Week Range
$66.57 – $203.91
Volume
$5.02B
Avg Volume
$4.09B
Shares Outstanding
77.2M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$8.25B
Last Q Revenue
$2.06B
P/E Ratio
183.4
P/S Ratio
1.5x
EPS (TTM)
$0.90
Dividend Yield
β€”

Why Investors Own ICLR

  • βœ“High-growth profile β€” revenue up -9.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 20% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$8.25Bβ–Ό βˆ’11.7% YoY
Gross Margin (TTM)
70.0%β–² +2.0% YoY
Operating Income (TTM)
$1.06Bβ–Ό βˆ’11.7% YoY
Free Cash Flow (TTM)
$1.63Bβ–Ό βˆ’11.7% YoY

About ICON PLC

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
51/100

Analyst Price Target

β“˜
Average Target
$796.16
β–Ό βˆ’3.3% Downside
High Target$896.17
Low Target$604.00
Based on 35 analysts

Latest News & Updates